Last reviewed · How we verify
CP690,550
CP690,550 is a JAK inhibitor that selectively blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation.
CP690,550 is a JAK inhibitor that selectively blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation. Used for Rheumatoid arthritis, Ulcerative colitis, Psoriasis.
At a glance
| Generic name | CP690,550 |
|---|---|
| Sponsor | Pfizer |
| Drug class | JAK inhibitor |
| Target | JAK1, JAK3 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
CP690,550 (tofacitinib) inhibits JAK1 and JAK3 kinases, which are critical for signal transduction downstream of cytokine receptors involved in immune and inflammatory responses. By blocking JAK signaling, the drug reduces the production of pro-inflammatory cytokines and suppresses T-cell proliferation and activation, thereby dampening pathological immune responses in autoimmune and inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Ulcerative colitis
- Psoriasis
- Polyarticular course juvenile idiopathic arthritis
Common side effects
- Upper respiratory tract infection
- Headache
- Diarrhea
- Nasopharyngitis
- Elevated cholesterol
Key clinical trials
- A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA (PHASE3)
- CP-690-550 Ointment For Chronic Plaque Psoriasis (PHASE2)
- CP-690,550 Thorough QTc Study (PHASE1)
- A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis (PHASE3)
- A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis (PHASE3)
- A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis (PHASE3)
- A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CP690,550 CI brief — competitive landscape report
- CP690,550 updates RSS · CI watch RSS
- Pfizer portfolio CI